These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 11495257

  • 1. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
    Pillai G, Ellard GA, Smith PJ, Fourie PB.
    Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
    [Abstract] [Full Text] [Related]

  • 2. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G, Fourie PB, Padayatchi N, Onyebujoh PC, McIlleron H, Smith PJ, Gabriels G.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [Abstract] [Full Text] [Related]

  • 3. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J, Jin H, Zhu H, Zheng M, Wang B, Liu C, Chen M, Zhou L, Zhao W, Fu L, Lu Y.
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [Abstract] [Full Text] [Related]

  • 4. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.
    Int J Pharm; 2004 May 19; 276(1-2):41-9. PubMed ID: 15113612
    [Abstract] [Full Text] [Related]

  • 5. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P, Ramachandran G, Vijayalakshmi S, Kumar AK, Venkatesan P, Chandrasekaran V, Vjayasekaran V, Kumaraswami V, Prabhakar R.
    Int J Tuberc Lung Dis; 1999 Feb 19; 3(2):119-25. PubMed ID: 10091876
    [Abstract] [Full Text] [Related]

  • 6. The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.
    McIlleron H, Gabriels G, Smith PJ, Fourie PB, Ellard GA.
    Int J Tuberc Lung Dis; 1999 Nov 19; 3(11 Suppl 3):S329-35; discussion S351-2. PubMed ID: 10593713
    [Abstract] [Full Text] [Related]

  • 7. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
    Padgaonkar KA, Revankar SN, Bhatt AD, Vaz JA, Desai ND, D'Sa S, Shah V, Gandewar K.
    Int J Tuberc Lung Dis; 1999 Jul 19; 3(7):627-31. PubMed ID: 10423226
    [Abstract] [Full Text] [Related]

  • 8. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
    Ellard GA.
    Int J Tuberc Lung Dis; 1999 Nov 19; 3(11 Suppl 3):S322-4; discussion S351-2. PubMed ID: 10593711
    [Abstract] [Full Text] [Related]

  • 9. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
    Zwolska Z, Niemirowska-Mikulska H, Augustynowicz-Kopec E, Walkiewicz R, Stambrowska H, Safianowska A, Grubek-Jaworska H.
    Int J Tuberc Lung Dis; 1998 Oct 19; 2(10):824-30. PubMed ID: 9783530
    [Abstract] [Full Text] [Related]

  • 10. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
    Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.
    Int J Clin Pharmacol Ther; 2002 Oct 19; 40(10):474-81. PubMed ID: 12395981
    [Abstract] [Full Text] [Related]

  • 11. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.
    Schall R, Müller FO, Duursema L, Groenewoud G, Hundt HK, Middle MV, Mogilnicka EM, Swart KJ.
    Arzneimittelforschung; 1995 Nov 19; 45(11):1236-9. PubMed ID: 8929247
    [Abstract] [Full Text] [Related]

  • 12. Bioequivalence of fixed-dose combination Myrin®-P Forte and reference drugs in loose combination.
    Wang HF, Wang R, O'Gorman M, Crownover P, Naqvi A, Jafri I.
    Int J Tuberc Lung Dis; 2013 Dec 19; 17(12):1596-601. PubMed ID: 24200275
    [Abstract] [Full Text] [Related]

  • 13. Establishment of a reference formulation for bioequivalence assessment of rifampicin-containing FDCs: an essential step towards improving tuberculosis treatment.
    Ashokraj Y, Singh I, Kaur KJ, Kohli G, Bhade SR, Varma MV, Kaul CL, Panchagnula R.
    Int J Tuberc Lung Dis; 2005 Jul 19; 9(7):791-6. PubMed ID: 16013776
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.
    Ellard GA, Fourie PB.
    Int J Tuberc Lung Dis; 1999 Nov 19; 3(11 Suppl 3):S301-8; discussion S317-21. PubMed ID: 10593709
    [Abstract] [Full Text] [Related]

  • 16. Modification to improve efficiency of sampling schedules for BA/BE testing of FDC anti-tuberculosis drugs.
    Gabriels GA, McIlleron H, Smith PJ, Folb PI, Fourie PB.
    Int J Tuberc Lung Dis; 2007 Feb 19; 11(2):181-8. PubMed ID: 17263289
    [Abstract] [Full Text] [Related]

  • 17. The colorimetric analysis of anti-tuberculosis fixed-dose combination tablets and capsules.
    Ellard GA.
    Int J Tuberc Lung Dis; 1999 Nov 19; 3(11 Suppl 3):S343-6; discussion S351-2. PubMed ID: 10593715
    [Abstract] [Full Text] [Related]

  • 18. Plasma pooling: utility in expediting bioequivalence assessment of rifampicin-containing fixed-dose combinations.
    Ashokraj Y, Singh I, Kaur KJ, Kohli G, Bhade SR, Varma MV, Kaul CL, Panchagnula R.
    Int J Tuberc Lung Dis; 2005 Jun 19; 9(6):697-9. PubMed ID: 15971401
    [Abstract] [Full Text] [Related]

  • 19. Plasma pooling to expedite bioequivalence estimation of rifampicin in fixed dose combinations.
    Panchagnula R, Parmar J, Kaur JK, Singh I, Bhade SR.
    Methods Find Exp Clin Pharmacol; 2006 Apr 19; 28(3):161-7. PubMed ID: 16810342
    [Abstract] [Full Text] [Related]

  • 20. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
    Singh S, Mohan B.
    Int J Tuberc Lung Dis; 2003 Mar 19; 7(3):298-303. PubMed ID: 12661847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.